Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)
Keros Therapeutics (KROS) posted Other Operating Expenses of -$1.5 million for Q1 2020, down 1810.26% on a QoQ basis from -$78000.0 in Q4 2019, and down 146.69% year-over-year from $3.2 million in Q2 2019.
Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020) Analysis & Trends
Keros Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$1.5 million for Q1 2020.
- Quarterly Other Operating Expenses fell 146.69% year-over-year to -$1.5 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was -$1.5 million (up 41.89% YoY) and the FY2020 annual result came in at -$1.5 million, up 41.89% from the prior year.
- Other Operating Expenses was -$1.5 million for Q1 2020 at Keros Therapeutics, down from -$78000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$78000.0 in Q4 2019 and bottomed at -$1.5 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -1.49 Mn |
| Dec 31, 2019 | -78,000.00 |
| Sep 30, 2019 | -1.24 Mn |
| Jun 30, 2019 | -647,000.00 |
| Mar 31, 2019 | -604,000.00 |